Suits on Biotech Rules Dismissed

WASHINGTON—Six months after the federal government published its set of proposed regulations governing biotechnology, two lawsuits aimed at overturning those regulations have failed. On December 22 Judge Gerhard A. Gesell of the U.S. District Court for the District of Columbia dismissed a suit filed by environmental activist Jeremy Rifkin that sought to overturn the June 26 announcement on the grounds that it bypassed established federal rulemaking procedures. The same day, Gesell dismisse

Written byGregory Byrne
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

On December 22 Judge Gerhard A. Gesell of the U.S. District Court for the District of Columbia dismissed a suit filed by environmental activist Jeremy Rifkin that sought to overturn the June 26 announcement on the grounds that it bypassed established federal rulemaking procedures.

The same day, Gesell dismissed as premature a separate suit brought by Rifkin to force the Environmental Protection Agency to require that agencies licensed to release genetically engineered materials into the environment be financially able to undo any damage done. Gesell ruled that Rifkin had shown no specific injury caused by the rules and that Rifkin had not established his legal standing to sue in the case.

Despite the suit's allegations, federal agencies had not adopted the rules, Judge Gesell said. "While the [June 26] document is not a model of clarity, its treatment by the agencies involved conclusively establishes it is merely a first effort ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies